Neuroendocrine tumors: a multidisciplinary approach for a complex disease

References

[1] Yao JC,Phan A,Leary C,Abdalla EK,Vauthey JN,Evans DB.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States..J Clin Oncol2008;26:3063-72

[2] Berardi R,Torniai M,Partelli S,Onofri A,Pagliaretta S,Cascinu S.Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy -- A literature review..Crit Rev Oncol Hematol2016;98:264-74

[3] Rinke A,Schade-Brittinger C,Barth P,Mayer C,Pape UF,Harder J,Gress T.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group..J Clin Oncol2009;27:4656-63

[4] Caplin ME,Ćwikła JB,Raderer M,Cadiot G,Capdevila J,Rindi G,Martinez S,Ruszniewski P.Lanreotide in metastatic enteropancreatic neuroendocrine tumours..N Engl J Med2014;371:224-33

[5] Hardiansyah D,Attarwala AA,Kletting P,Glatting G.The role of patient-based treatment planning in peptide receptor radionuclide therapy..Eur J Nucl Med Mol Imaging2016;43:871-80

[6] Vilar E,Perez-Garcia J,Oberg K.Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumours..Endocr Relat Cancer2007;14:221-32

[7] Rindi G,Bosman FT,Klimstra DS,Komminoth P.Nomenclature and classification of neuroendocrine neoplasms of the digestive system..In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds).2010;LyonIARC Press13-4